Clinical trial

Propolis as a Treatment Option for Hand Foot and Mouth Disease

Name
HMFD-24
Description
Hand foot and mouth disease (HFMD) is a frequently self-limited viral infectious disease in children with no specific antiviral treatment option. There has been an increasing interest in bee products in recent years, and propolis has come to the fore with its high therapeutic and protective effect. Although the inhibitory effect of propolis against enteroviruses (EVs) has been shown in studies, there is no clinical data regarding its use in the course of HFMD. The aim of this prospective multicenter randomized clinical study was to evaluate the effect of propolis use in children with HFMD. The patients were randomly assigned to have Anatolian propolis or no supplement - control group in addition to symptomatic therapy decided by the physician. The duration of the patients' complaints, the distribution of the lesions in the body, and the fever status were recorded on admission. Parents were asked to rate the severity of the child's restlessness, inappetence, and sleeplessness status on a scale of 0-10 on the initial, 2nd (at 48th hour), and 3rd (on 5-7 days) visits.
Trial arms
Trial start
2019-01-01
Estimated PCD
2022-01-01
Trial end
2023-01-01
Status
Completed
Phase
Early phase I
Treatment
Propolis
Propolis 3x10 drops (7 days)
Arms:
Propolis group
Size
200
Primary endpoint
Propolis treatment
48 hours and 7 days
Eligibility criteria
Inclusion Criteria: * Patients diagnosed with HMFD * 1-10 years old Exclusion Criteria: * The patients whose complaints were longer than 48 hours, * those whose parents stated that they could not comply with the follow ups, * those who were taking another antiviral or supportive treatment, * those who had used antibiotics in the last 1 month, * those with a history of immunodeficiency or a family history of immunodeficiency, * those who had a history of anaphylaxis with any support product or drug, * patients with a chronic disease or skin lesion
Protocol
{'studyType': 'INTERVENTIONAL', 'phases': ['PHASE2', 'PHASE3'], 'designInfo': {'allocation': 'RANDOMIZED', 'interventionModel': 'PARALLEL', 'interventionModelDescription': 'control and treatment group', 'primaryPurpose': 'TREATMENT', 'maskingInfo': {'masking': 'NONE', 'maskingDescription': 'Patients in both groups were prescribed antipyretics and antihistamines when deemed appropriate by the clinician. Propolis 3x10 drops (7 days) were used in the propolis group. Both the investigators and the patients were aware of the drug being given.\n\nA computerized randomization program was used for group selection.'}}, 'enrollmentInfo': {'count': 200, 'type': 'ACTUAL'}}
Updated at
2024-06-12

1 organization

1 product

2 indications

Organization
Murat Sutcu
Product
Propolis